Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 2891-2908

  Wu, Jason Boyang ^a   Shao, Chen ^a,b   Li, Xiangyan ^a   Li, Qinlong ^a,b   Hu, Peizhen ^a,b   Shi, Changhong ^a   Li, Yang ^c   Chen, Yi Ting ^a   Yin, Fei ^c   Liao, Chun Peng ^a,d   Stiles, Bangyan L ^c   Zhau, Haiyen E ^a   Shih, Jean C ^c,e   Chung, Leland W K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NEUROPILIN 1; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR TWIST; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LNCAP CELL LINE; METASTASIS; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR XENOGRAFT;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; DISEASE PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MICE, SCID; MODELS, BIOLOGICAL; MONOAMINE OXIDASE; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TWIST TRANSCRIPTION FACTOR; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903795515     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70982     Document Type: Article

References (85)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Partin AW, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277(18):1445-1451.
3. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999; 22:197-217. (Pubitemid 29144886)
4. Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J Neural Transm. 2011;118(7):979-986.
5. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008;60(13-14):1527-1533.
6. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579-591.
7. True L, et al. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A. 2006;103(29):10991-10996. (Pubitemid 44148406)
8. Peehl DM, Coram M, Khine H, Reese S, Nolley R, Zhao H. The significance of monoamine oxidase-A expression in high grade prostate cancer. J Urol. 2008;180(5):2206-2211.
9. Zhao H, Nolley R, Chen Z, Reese SW, Peehl DM. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differentiation. 2008;76(7):820-830.
10. Nauseef JT, Henry MD. Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol. 2011;8(8):428-439.
11. Stewart GD, Ross JA, McLaren DB, Parker CC, Habib FK, Riddick AC. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010;105(1):8-13.
12. Gupta-Elera G, Garrett AR, Robison RA, O'Neill KL. The role of oxidative stress in prostate cancer. Eur J Cancer Prev. 2012;21(2):155-162.
13. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.
14. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res. 2010;16(24):5928-5935.
15. Finley LW, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1βdestabilization. Cancer Cell. 2011;19(3):416-428.
16. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402. (Pubitemid 351681994)
17. Schnaitman C, Erwin VG, Greenawalt JW. The submitochondrial localization of monoamine oxidase. An enzymatic marker for the outer membrane of rat liver mitochondria. J Cell Biol. 1967;32(3):719-735.
18. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995;92(12):5510-5514.
19. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc Natl Acad Sci U S A. 1998;95(20):11715-11720. (Pubitemid 28460480)
20. Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets. 2012;16(4):365-376.
21. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998;92(6):735-745. (Pubitemid 28155313)
22. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1):121-130.
23. Zhang Y, Gan B, Liu D, Paik JH. FoxO family members in cancer. Cancer Biol Ther. 2011;12(4):253-259.
24. Bachelder RE, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res. 2001;61(15):5736-5740. (Pubitemid 32769088)
25. Yang J, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004;117(7):927-939. (Pubitemid 38798858)
26. Wallerand H, et al. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol. 2010;28(5):473-479.
27. Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA. PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene. 2010;29(24):3554-3565.
28. Xue G, et al. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt TGF-beta signaling axes. Cancer Discov. 2012;2(3):248-259.
29. Shiota M, et al. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, E-cadherin regulation. Clin Cancer Res. 2010;16(23):5654-5663.
30. Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem. 1999;274(24):16741-16746.
31. Cheng GZ, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem. 2008;283(21):14665- 14673.
32. Glauser DA, Schlegel W. The emerging role of FOXO transcription factors in pancreatic βcells. J Endocrinol. 2007;193(2):195-207.
33. Allen DL, Unterman TG. Regulation of myostatin expression and myoblast differentiation by FoxO and SMAD transcription factors. Am J Physiol Cell Physiol. 2007;292(1):C188-C199. (Pubitemid 46115130)
34. Fan W, et al. FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages. EMBO J. 2010;29(24):4223-4236.
35. Zhau HY, et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A. 1996; 93(26):15152-15157. (Pubitemid 27009568)
36. Thalmann GN, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994;54(10):2577-2581. (Pubitemid 24173741)
37. Green AR, Youdim MB. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain hyperactivity following subsequent tryptophan administration. Br J Pharmacol. 1975;55(3):415-422.
38. Wu TT, et al. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer. 1998;77(6):887-894. (Pubitemid 28378138)
39. Xu J, et al. Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 2006;66(15):1664-1673. (Pubitemid 44646357)
40. Tomlins SA, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310(5748):644-648. (Pubitemid 41528150)
41. Potter SR, Epstein JI, Partin AW. Seminal vesicle invasion by prostate cancer: prognostic significance and therapeutic implications. Rev Urol. 2000; 2(3):190-195.
42. Hodorova I, et al. Comparison of expression pattern of monoamine oxidase A with histopathologic subtypes and tumour grade of renal cell carcinoma. Med Sci Monit. 2012;18(12):BR482-BR486.
43. Rybaczyk LA, Bashaw MJ, Pathak DR, Huang K. An indicator of cancer: downregulation of monoamine oxidase-A in multiple organs and species. BMC Genomics. 2008;9:134.
44. Gurel B, et al. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol. 2008;21(9):1156-1167.
45. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999;59(17):4291-4296 (Pubitemid 29418745)
46. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst. 1994;86(12):926-933.
47. Pratesi G, Cervi S, Balsari A, Bondiolotti G, Vicentini LM. Effect of serotonin and nicotine on the growth of a human small cell lung cancer xenograft. Anticancer Res. 1996;16(6B):3615-3619 (Pubitemid 27085021)
48. Soll C, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology. 2010; 51(4):1244-1254.
49. Lee HJ, Park MK, Kim SY, Park Choo HY, Lee AY, Lee CH. Serotonin induces melanogenesis via serotonin receptor 2A. Br J Dermatol. 2011 165(6):1344-1138.
50. Alpini G, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 2008;68(22):9184-9193.
51. Malorni W, et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett. 1998; 426(1):155-159. (Pubitemid 28198175)
52. Huang L, et al. Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events. Lab Invest. 2012;92(10):1451-1460.
53. Pirozhok I, Meye A, Hakenberg OW, Fuessel S, Wirth MP. Serotonin and melatonin do not play a prominent role in the growth of prostate cancer cell lines. Urol Int. 2010;84(4):452-460.
54. Jungwirth N, Haeberle L, Schrott KM, Wullich B, Krause FS. Serotonin used as prognostic marker of urological tumors. World J Urol. 2008;26(5):499-504.
55. Heinrich E, et al. Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin-impact on angiogenesis and clinical follow-up. Prostate. 2011;71(16):1752-1758.
56. Savagner P. The epithelial-mesenchymal tran-sition (EMT) phenomenon. Ann Oncol. 2010; 21(suppl 7):vii89-vii92.
57. Behnsawy HM, Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int. 2013;111(1):30-37.
58. Bonello S, et al. Reactive oxygen species activate the HIF-1αpromoter via a functional NFκB site. Arterioscler Thromb Vasc Biol. 2007;27(4):755-761. (Pubitemid 46606703)
59. Chandel NS, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxiainducible factor-1βduring hypoxia: a mechanism of O2 sensing. J Biol Chem. 2000;275(33):25130-25138.
60. Geha RM, Chen K, Wouters J, Ooms F, Shih JC. Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling. J Biol Chem. 2002;277(19):17209-17216. (Pubitemid 34967754)
61. Guttmann-Raviv N, Kessler O, Shraga-Heled N, Lange T, Herzog Y, Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression. Cancer Lett. 2006;231(1):1-11. (Pubitemid 41779447)
62. Matsushita A, Gotze T, Korc M. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Res. 2007; 67(21):10309-10316. (Pubitemid 350070805)
63. Hu B, et al. Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene. 2007; 26(38):5577-5586. (Pubitemid 47267840)
64. Glinka Y, Prud'homme GJ. Neuropilin-1 is a receptor for transforming growth factor β-1, activates its latent form, promotes regulatory T cell activity. J Leukoc Biol. 2008;84(1):302-310. (Pubitemid 351960305)
65. Cao S, et al. Neuropilin-1 promotes cirrhosis of the rodent human liver by enhancing PDGF/TGF-β signaling in hepatic stellate cells. J Clin Invest. 2010; 120(7):2379-2394.
66. Vesuna F, van Diest P, Chen JH, Raman V. Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer. Biochem Biophys Res Commun. 2008;367(2):235-241.
67. Yang MH, et al. Direct regulation of TWIST by HIF-1βpromotes metastasis. Nat Cell Biol. 2008; 10(3):295-305.
68. Mak P, et al. ERbeta impedes prostate cancer EMT by destabilizing HIF-1βand inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell. 2010;17(4):319-332.
69. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011;9(12):1644-1657.
70. Shiota M, et al. Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene. 2010;29(2):237-250.
71. Shiota M, et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res. 2008; 68(1):98-105. (Pubitemid 351380110)
72. Zhau HE, et al. Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis. 2008; 25(6):601-610.
73. Zeng N, et al. PTEN controls beta-cell regeneration in aged mice by regulating cell cycle inhibitor p16(ink4a.). Aging Cell. 2013;12(6):1000-1011.
74. Wu JB, Chen K, Ou XM, Shih JC. Retinoic acid activates monoamine oxidase B promoter in human neuronal cells. J Biol Chem. 2009; 284(25):16723-16735.
75. Zeng N, et al. Adaptive basal phosphorylation of eIF2alpha is responsible for resistance to cellular stress-induced cell death in Pten-null hepatocytes. Mol Cancer Res. 2011;9(12):1708-1717.
76. Chen K, Ou XM, Wu JB, Shih JC. Transcription factor E2F-associated phosphoprotein (EAPP), RAM2/CDCA7L/JPO2 (R1), simian virus 40 promoter factor 1 (Sp1) cooperatively regulate glucocorticoid activation of monoamine oxidase B. Mol Pharmacol. 2011;79(2):308-317.
77. Wu JB, Shih JC. Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol Pharmacol. 2011;80(4):714-723.
78. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol. 2010;594:57-72.
79. Li Y, et al. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) signaling regulates mitochondrial biogenesis respiration via estrogen-related receptor &).?beta;(ERR J Biol Chem. 2013; 288(35):25007-25024.
80. Graham JM. Isolation of mitochondria from tissues and cells by differential centrifugation. Curr Protoc Cell Biol. 2001;3:Unit 3.3.
81. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24(3):148-154. (Pubitemid 19163397)
82. Fischer AH, Jacobson KA, Rose J, Zeller R. Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2008;2008:pdb.prot4986
83. Wu JB, Chen K, Li Y, Lau YF, Shih JC. Regulation of monoamine oxidase A by the SRY gene on the Y chromosome. FASEB J. 2009;23(11):4029-4038.
84. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11-22.
85. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004;113(6):913-923. (Pubitemid 38544150)